From role models to open doors, Christina Y. Weng, MD, MBA, FASRS, shares insights on career development, women in ophthalmology, evolving training models, and her work as protocol chair for the DRCR ...

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Drs. Do, Lad, and Munk about the LIGHTSITE III trial data behind photobiomodulation and what ...

Although my practice is primarily an anterior segment practice, the care of patients with age-related macular degeneration (AMD) is something I have always followed closely. AMD is the leading cause ...

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...

Expert retina specialists discuss recent developments in the treatment landscape for geographic atrophy (GA) and the future management of patients with coexisting neovascular AMD and GA.

This phase 2b study (ASPIRE) is currently underway. UNITY believes that its lead candidate, UBX1325 (foselutoclax), with its unique mechanism of action, has the potential to improve long-term visual ...

María Berrocal, MD, titled her Kreissig Award Lecture "Throwing away wisdom: How we abandon what works." María Berrocal, from Drs. Berrocal and Associates in San Juan, Puerto Rico, delivered the ...

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15. The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial.

The investigators use mindfulness-based cognitive therapy (MBCT) on patients who have never previously practiced the technique, with the aim of possibly re-training their brains to remove their static ...

Results were published from the phase 3 QUASAR trial and the extension study of the phase 3 PULSAR trial. Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its ...